Core--Tissue

核心--组织

• 批准号: 6594422
• 负责人: LAURA Z RASSENTI
• 金额: $ 16.54万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-05-31 至 2003-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6594422
• 关键词: biomedical facility; cancer registry /resource; chronic lymphocytic leukemia; human subject; sample collection; tissue /cell preparation; tissue resource /registry

1) To receive, process, and store blood samples in an efficient and organized manner from CLL patients that have been diagnosed at various sites across the country. The first step will involve collecting, processing, labeling, and storing the sample received from each patient. The second step will be the distribution of the sample to various sites for addition studies as requested by the investigators of the CRC. In addition, the Tissue Core will assure accurate quality control, record keeping, and data management. Approximately 2,000 samples will be collected per year. 2) To provide a central repository for CLL blood samples with basic minimum information. When the samples are received by the Tissue Core, they will be assigned a unique patient identifier number and logged into a database. This database will be updated as information is received on the subsequent samples that are collected from the CLL patients. 3) To make the viably frozen samples readily available to the CRC investigators for future research studies. The investigators of the CRC will be able to request frozen vials needed for event-driven studies (hypothesis testing) by submitting a sample request a sample request form. This form requires a description of the proposed hypothesis, the outcome of the project, the biostatistician appraisal, the number & type of samples required, and the approval of the advisory committee. 4) To perform basic panel of tests. The basic tests that will be conducted on each patient sample as it is newly diagnosed will be: A- immunophenotyping analysis (Flow cytometry) to assess extent of disease and B- (AN-PCR-ELISA) to determine expressed Ig VH subgroup. Cytogenetic Minimal Residual Disease (MRD), and Los of Heterozygosity (LOH) testing will be performed on specific CLL samples only according to hypothesis-driven studies. These studies will be outlined in the sample request forms that will be received by the Tissue Core director and evaluated.

1）从全国各地诊断出的CLL患者中以有效且有组织的方式接收，处理和存储血液样本。第一步将涉及收集，处理，标签和存储从每个患者那里收到的样本。第二步将是按照CRC的研究人员要求将样品分布到各个地点进行添加研究。此外，组织核心将确保准确的质量控制，记录保存和数据管理。每年将收集大约2,000个样本。 2）为CLL血样提供基本最小信息的中央存储库。当组织核心接收样品时，将分配一个唯一的患者标识符编号并登录到数据库中。随着从CLL患者收集的后续样品收到信息，该数据库将进行更新。 3）使CRC研究人员很容易地将样品易于冷冻，以进行未来的研究。 CRC的研究人员将能够通过提交样本请求示例请求表格，要求事件驱动的研究（假设测试）所需的冷冻小瓶。此表格需要描述拟议的假设，项目的结果，生物统计学家评估，所需的样本数量和类型以及咨询委员会的批准。 4）执行基本测试面板。新诊断为每个​​患者样本的基本测试将是：A-免疫表型分析（流式细胞仪），以评估疾病和B-（AN-PCR-ELISA）的程度，以确定表达的IG VH亚组。仅根据假设驱动的研究，才能对特定的CLL样品进行细胞遗传学最小残留疾病（MRD）和杂合性（LOH）测试的LO。这些研究将以组织核心主管将收到并进行评估的样本请求表中概述。